Floatz logo

Aclarubicin

Cutaneous T Cell Lymphoma (CTCL)

Shanghai Jiao Tong University School of MedicineSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cutaneous T Cell Lymphoma (CTCL) cohort.

Asset / SponsorPhaseRating
Nm-Il-12
Neumedicines Inc.
Phase 2CCC
il-15
National Cancer Institute (NCI)
Phase 1CC
dt-7012
Assistance Publique - Hôpitaux de Paris
Early Phase 1C

Same molecule, other indications

Aclarubicin is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →
Induction ChemotherapyDormant
B
Indicative ·
60 / 100
View asset →
LisaftoclaxDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →